教育背景

1995-1999 安徽农业大学 学士

2002-2005 中国科学院微生物研究所 博士

工作经历

2006-2013 美国贝勒免疫研究所 博士后 

2014-2024 清华大学医学院 副研究员

2024-至今 清华大学基础医学院 副研究员

研究领域

人体免疫学与疾病。囊膜病毒的感染机制：对囊膜病毒入侵宿主细胞以及宿主产生的免疫应答进行研究。通过对新冠肺炎康复者的体液和细胞免疫反应进行研究，发现患者清除病毒后机体能产生保护性的适应性免疫反应；靶向树突状细胞的疫苗：设计靶向树突状细胞的疫苗，接种后对抗原特异性的抗体和细胞免疫反应进行分析，并比较靶向树突状细胞不同受体分子引起的适应性免疫应答反应；肿瘤免疫：通过对临床上切除的肿瘤样本进行系统分析发现新的肿瘤免疫治疗的靶点，同时利用小鼠肿瘤模型对肿瘤浸润的CD8⁺ T细胞耗竭机制进行研究。

科学贡献

通过小鼠肿瘤模型以及肿瘤患者的临床标本发现了新型的B7免疫检查点分子，B7-H3,B7S1以及VISTA，对肿瘤患者的免疫治疗提供了新的靶分子；在国内外首次发现新冠患者适应性免疫应答反应特征，为疫苗的设计和优化提供了新的理论支撑；同时，还从事免疫转化相关的工作，搭建了免疫平台，已为国际制药公司提供多项技术支持。以第一或通讯作者的身份发表在Immunity、Cellular & molecular immunology等杂志发表学术论文23篇，共发表学术论文58篇，引用近4千次。在此期间，申请专利2项并授权1项。担任vaccines、Frontiers in immunology等杂志编委。

荣誉奖励

2010 AAI青年教师和学员奖

2009 FOCIS旅行奖

2006 谈家桢基金九源奖学金

代表性论文

1.Jing Hao, Ruifeng Li, Xiaohong Zhao, Xinwei Liu, Xiang Chen, Tian Xie, Xiaoli Li, Chenjun Yao, Qinli Sun, Kun Wei, Mengting Gou, Xinxin Chi, Wei Xu, Ling Ni, Chen Dong. NR4A1 transcriptionally regulates the differentiation of stem-like CD8+ T cells in the tumor microenvironment. Cell reports, 2024. 43 (6), 114301.

2.Qinli Sun, Dongli Cai, Dingfeng Liu, Xiaohong Zhao, Ruifeng Li, Wei Xu, Bowen Xie, Mengting Gou, Kun Wei, Yuling Li, Jinling Huang, Xinxin Chi, Peng Wei, Jing Hao, Xinyi Guo, Birui Pan, Yujie Fu, Ling Ni, Chen Dong. BCL6 promotes a stem-like CD8+ T cell program in cancer via antagonizing BLIMP1. Science Immunology, eadh1306, 2023.

3.Ling Ni*. Advances in mRNA-based cancer vaccines. Vaccines 2023, Volume 11, Issue 10, 1599.

4.Guang-Wei Feng, Zhong-Fang Wang, Peng He, Qin-Ying Lan, Ling Ni, Ya-Zheng Yang, Chen-Fei Wang, Ting-Ting Cui, Li-Li Huang, Yong-Qiang Yan, Zhi-Wei Jiang, Qing Yang, Bang-Wei Yu, Xi Han, Jing-Jing Chen, Shu-Yuan Yang, Lin Yuan, Ling-Yun Zhou, Ge Liu, Ke Li, Zhen Huang, Jin-Cun Zhao, Zhong-Yu Hu, Zhi-Qiang Xie. Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial. Hum Vaccin Immunother. 2023,37881130.

5.Ling Ni*, Jingtao Chen*, Mi Deng*, Haidong Tang*, Musheng Bao*. Involvement of dendritic cells in Gastrointestinal cancer. Frontiers in immunology. 2023.

6.Qinli Sun, Xiaohong Zhao, Ruifeng Li, Dingfeng Liu, Birui Pan, Bowen Xie, Xinxin Chi, Dongli Cai, Peng Wei, Wei Xu, Kun Wei, Zixuan Zhao, Yujie Fu, Ling Ni, and Chen Dong.* STAT3 regulates CD8⁺ T cell differentiation and functions in cancer and acute infection. Journal of Experimental Medicine. 2023.

7.Xinwei Liu, Jing Hao, Peng Wei, Xiaohong Zhao, Qiuyan Lan, Lu Ni, Yongzhen Chen, Xue Bai, Ling Ni, Chen Dong*. SMAD4, activated by the TCR-triggered MEK/ERK signaling pathway, critically regulates CD8+ T cell cytotoxic function. Science Advance. 2022.

8.Ling Ni. Advances in human dendritic cell-based immunotherapy against gastrointestinal cancer. Frontiers in immunology. 2022.

9.Shanjuan Hong#, Qing Yuan#, Haizhui Xia, Yuan Dou, Tiantian Sun, Tian Xie, Zhiyin Zhang, Wei He, Chen Dong, Jian Lu*, Li Guo*, Ling Ni*. Establishment of an ex vivo tissue culture model for evaluation of anti-tumor efficacy in clear cell renal cell carcinoma. Frontiers in oncology. 2022.

10.Ling Ni #,* Fang Ye#, Qin Qiao#, Yu Feng, Yazheng Yang, Hui Zhao, Li-nan Zhang, Meng-Li Cheng, Gengzhen Zhu, Xiaoli Li, Xuan Zhong, Ruifeng Li, Cheng-Feng Qin, Fang Chen*, Chen Dong*. Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual. National science open, 2022.

11.Yu Feng#, Liguo Liu#, Jing Li, Jia Huang, Jenny H. Xie, Laurence Menard, Yanfen Shi, Xiaohong Zhao, Shan Xie, Wenjuan Zang, Haidong Tan, Zhiying Yang* and Ling Ni*. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target. Oncology reports, 2022, 48.

12.Gui-Ling Chen^#, Xiao-Feng Li^#, Xia-Hong Dai^#, Nan Li ^#, Meng-Li Cheng^#, Zhen Huang^#, Jian Shen, Yu-Hua Ge, Zhen-Wei Shen, Yong-Qiang Deng, Shu-Yuan Yang, Hui Zhao, Na-Na Zhang, Yi-Fei Zhang, Ling Wei, Kai-Qi Wu, Meng-Fei Zhu, Cong-Gao Peng, Qi Jiang, Shou-Chun Cao, Chang-Gui Li, Yu-Hua Li, Ling Ni, Huahao Shen, Chen Dong, Bo Ying^*, Guo-Ping Sheng^*, Cheng-Feng Qin^*, Hai-Nv Gao^*, Lan-Juan Li^*. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomized, double-blind, placebo-controlled, phase 1 trial. The Lancet Microbe. 2022.

13.Haizhui Xia#, Decao Yang#, Wei He, Xuehua Zhu, Ye Yan, Zenan Liu, Tong Liu, Jianling Yang, Shi Tan, Jie Jiang, Xiaofei Hou, Huile Gao, Ling Ni and Jian Lua*. Ultrasound-mediated microbubbles cavitation enhanced chemotherapy of advanced prostate cancer by increasing the permeability of blood-prostate barrier. Translational Oncology. 2021,14.

14.Ling Ni#, Meng-Li Cheng#, Yu Feng#, Hui Zhao#, Jingyuan Liu, Fang Ye, Qing Ye, Gengzhen Zhu, Xiaoli Li, Pengzhi Wang, Jing Shao, Yong-Qiang Deng, Peng Wei, Fang Chen, Cheng-Feng Qin, Guoqing Wang, Fan Li*, Hui Zeng*, Chen Dong*. Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients. Frontiers in immunology. 2021,12.

15.Ling Ni#, Fang Ye#, Meng-Li Cheng#, Yu Feng, Yong-Qiang Deng, Hui Zhao, Peng Wei, Jiwan Ge, Mengting Gou, Xiaoli Li, Lin Sun, Tianshu Cao, Pengzhi Wang, Chao Zhou, Rongrong Zhang, Peng Liang, Han Guo, Xinquan Wang, Cheng-Feng Qin*, Fang Chen*, Chen Dong*. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020, 52, 971-977.

16.Ling Ni, Yu Feng, Chen Dong*. The advancement of immunotherapy in HCC. Hepatoma Research. 2020. 6:25-37.

17.Dongli Cai, Jiaming Li, Dingfeng Liu, Shanjuan Hong, Qin Qiao, Qinli Sun, Pingping Li, Nanan Lyu, Tiantian Sun, Shan Xie, Li Guo, Ling Ni*, Liping Jin*, Chen Dong*. Tumor-expressed B7-H3 mediates the inhibition of antitumorT-cell functions in ovarian cancer insensitive to PD-1blockade therapy. Cellular&molecular immunology. 2020. 17(3):227-236.

18.Shanjuan Hong, Qing Yuan, Haizhui Xia, Genzhen Zhu, Yu Feng, Qiang Wang, Zhiyin Zhang, Wei He, Jian Lu*, Chen Dong*, Ling Ni*. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein&cell. 2019.10(11):840-845. (IF: 7.575)

19.Xindong Liu, Yun Wang, Huiping Lu, Jing Li, Xiaowei Yan, Minglu Xiao, Jing Hao, Andrei Alekseev, Hiep Khong, Tenghui Chen, Rui Huang, Jin Wu, Qiwen Zhao, Qi Wu, Senlin Xu, Xiaohu Wang, Wei Jin, Shicang Yu, Yan Wang, Lai Wei, Aibo Wang, Bo Zhong, Ling Ni, Xiaolong Liu, Roza Nurieva, Lilin Ye, Qiang Tian, Xiu-Wu Bian* & Chen Dong*. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature. 2019; 567 (7749):525-529.

20.Jing Li, Yi He, Jing Hao, Ling Ni, and Chen Dong*. High levels of Eomes promotes exhaustion of anti-tumor CD8⁺ T cells. Frontiers in immunology. 2018; 9:1-14.

21.Shan Xie, Jia Huang, Qin Qiao, Wenjuan Zang, Shanjuan Hong, Haidong Tan, Chen Dong, Zhiying Yang*, Ling Ni*. Expression of inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunology, Immunotherapy. 2018, 67:1685-1694.

22.Ling Ni* and Jian Lu*. Inferferon gamma in cancer immunotherapy. Cancer medicine. 2018; 7(9): 4509-4516.

23.Ling Ni* and Chen Dong*. Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Frontiers in immunology. 2018; 9: 1-12.

24.Jing Li, Younghee Lee, Yanjian Li, Yu Jiang, Huiping Lu, Wenjuan Zang, Xiaohong Zhao, Liguo Liu, Yang Chen, Haidong Tan, Zhiying Yang, Michael Q. Zhang, Tak W. Mak, Ling Ni and Chen Dong*. B7S1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8⁺ T cells. Immunity. 2018; 48(4):773-786.

25.Ling Ni*. Comparison of PD-L1 and B7-H3 in cancer immunotherapy. Journal of immunology and immunotherapy. 2017; 1(1): 1-3.

26.Ling Ni*. Non-redundant roles of new immune checkpoints in cancer evasion. Immunotherapy. 2017; 3(3):144-145.

27.Younghee Lee #, Natalia Martin-Orozco, Peilin Zheng, Jing Li, Peng Zhang, Haidong Tan, Hyun Jung Park, Mira Jeong, Seon Hee Chang, Byung-Seok Kim, Wei Xiong, Wenjuan Zang, Li Guo, Yang Liu, Zhong-jun Dong, Wilem W Overwijk, Patrick Hwu, Qing Yi, Larry Kwak, Zhiying Yang, Tak W Mak, Wei Li, Laszlo G Radvanyi, Ling Ni, Dongfang Liu and Chen Dong*. Inhibition of B7-H3 checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Research. 2017; 27(8): 1034-1045.

28.Ling Ni*, Chen Dong. New B7 family checkpoints in human cancers. Mol Cancer Ther. 2017; 16 (7): 1203-1211.

29.Ling Ni*, Chen Dong*. New checkpoints in cancer immunotherapy. Immunological reviews. 2017; 276(1): 52-65.

30.Jing Li, Ling Ni, Chen Dong*. Immune checkpoint receptors in cancer: redundant by design? Current opinion in immunology. 2017; 45:37-42.

31.Wenjie Yin, Laurent Gorvel, Sandra Zurawski, Dapeng Li, Ling Ni, Dorothée Duluc, Katherine Upchurch, JongRok Kim, Chao Gu, Richard Ouedraogo, Zhiqing Wang, Yaming Xue, HyeMee Joo, Jean-Pierre Gorvel, Gerard Zurawski, SangKon Oh*. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells, EBioMedicine, 2016.

32.HyeMee Joo#, Katherine Upchurch, Wei Zhang, Ling Ni, Dapeng Li, Yaming Xue, Xiaohua Li, Toshiyuki Hori, Sandra Zurawski, Yong-Jun Liu, Gerard Zurawski, SangKon Oh *. Opposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization. Journal of immunology, 2015, 195(4): 1723-31

33.Dorothee Duluc, HyeMee Joo, Ling Ni, Yaming Xue, Peter Klucar, Sandra Zurawski, Gerard Zurawski, and SangKon Oh*. Signals via TCRs and common -chain receptors coordinate generation of antigen-derived peptide-specific human Th17. Journal of immunology, 2014, 192(12): 5776-88.

34.Dorothee Duluc, Julien Gannevat, HyeMee Joo, Ling Ni, Katherine Upchurch, Muriel Boreham, Michael Carley, Jack Stecher, Gerard Zurawski, SangKon Oh*. Dendritic cells and vaccine design for sexually-transmitted diseases, Microbial Pathogenesis, 2012, 1-10

35.Anne-Laure Flama, Sandra Zurawski, Felix Scholz, Ingrid Gayet, Ling Ni, Xiao-Hua Li, Eynav Klechevsky, John Quinn, Sangkon Oh, Daniel H. Kaplan, Jacques Banchereau, and Gerard Zurawski*. Non-covalent Assembly of Anti-Dendritic Cell Antibodies and Antigens for Evoking Immune Responses in vitro and in vivo. Journal of immunology, 2012 189(5): 2645-55.

36.Hideki Ueno #*, Eynav Klechevsky, Nathalie Schmitt, Ling Ni, Anne-Laure Flama, Sandra Zurawski, Gerard Zurawski, Karolina Palucka, Jacques Banchereau, SangKon Oh *. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011, 23(1): 21-7.

37.Ling Ni, Ingrid Gayet, Sandra Zurawski, Dorothee Duluc, Anne-Laure Flamar, Xiao-Hua Li, Amy O’Bar, Anna Karolina Palucka, Gerard Zurawski, Jacques Banchereau, and SangKon Oh*. Concomitant activation and antigen uptake via human Dectin-1 results in potent antigen-specific CD8+ T cell responses. Journal of immunology. 2010, 185(6): 3504-13.

38.Dullaers Mellisa, Li Dapeng, Xue Yaming, Ni Ling, Gayet Ingrid, Morita Rempei, Ueno Hide, Palucka Karolina, Banchereau Jacques, Oh Sangkon. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity. 2009 (1): 120-9

39.SangKon Oh, Liyanage P. Perera, Masaki Terabe, Ling Ni, Thomas A. Waldmann, and Jay A. Berzofsky*. IL-15 as a mediator of CD4⁺ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A. 2008 (13): 5201-6.

40.Ling Ni, Linqing Zhao, Jieqing Zhu, Zhibo Jin, Po Tien and George F. Gao*. Design and characterization of human respiratory syncytial virus entry inhibitors. Antiviral Therapy, 2005 (7): 833-40

41.Ling Ni, Jieqing Zhu, Junjie Zhang, Meng Yan, George F. Gao*, Po Tien*. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. Biochemical and Biophysical research communications, 2005 (330): 39-45.

42.Ling Ni, Linqing Zhao, George F. Gao, Yuan Qian and Po Tien*. The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro. Biochemical and Biophysical research communications, 2005 (331): 1358-1364.

43.Ling Ni, George F. Gao，Po Tien. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochemical and Biophysical research communications, 2005(332): 831-836.

44.Yanhui Xu, Jieqing Zhu, Yiwei Liu, Zhiyong Lou, Fang Yuan, Yueyong Liu, David K. Cole, Ling Ni, Nan Su, Lan Qin, Xu Li, Zhihong Bai, John I. Bell, Hai Pang, Po Tien, George F. Gao, and Zihe Rao. Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus. Biochemistry, 2004(43): 14064-14071.

45.Ling Ni, Zhiqiang Wang, Jinyong Dai, Like Jiang. Study on derect purification to Kunitz inhibitor from bovine lungs with trypsin fixed by modified chitosan. Natural Product Research and Development, 2002 (2): 42-46.